135 related articles for article (PubMed ID: 14675312)
41. Cytoreductive surgery combined with organ resection for advanced ovarian carcinoma.
Todo Y; Sakuragi N; Oikawa M; Negishi H; Yamamoto R; Yoshiaki K; Tsumura N; Kawaguchi I; Fujimoto S
Int J Clin Oncol; 2003 Apr; 8(2):90-6. PubMed ID: 12720101
[TBL] [Abstract][Full Text] [Related]
42. A novel technique: Carbon dioxide gas-assisted total peritonectomy, diaphragm and intestinal meso stripping in open surgery for advanced ovarian cancer (Çukurova technique).
Khatib G; Guzel AB; Gulec UK; Vardar MA
Gynecol Oncol; 2017 Sep; 146(3):674-675. PubMed ID: 28720378
[TBL] [Abstract][Full Text] [Related]
43. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.
Luyckx M; Leblanc E; Filleron T; Morice P; Darai E; Classe JM; Ferron G; Stoeckle E; Pomel C; Vinet B; Chereau E; Bergzoll C; Querleu D
Int J Gynecol Cancer; 2012 Oct; 22(8):1337-43. PubMed ID: 22964527
[TBL] [Abstract][Full Text] [Related]
44. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with peritoneal hepatocellular carcinoma.
Tabrizian P; Franssen B; Jibara G; Sweeney R; Sarpel U; Schwartz M; Labow D
J Surg Oncol; 2014 Dec; 110(7):786-90. PubMed ID: 25091997
[TBL] [Abstract][Full Text] [Related]
45. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma.
Eisenkop SM; Friedman RL; Spirtos NM
Cancer; 2000 Jan; 88(1):144-53. PubMed ID: 10618617
[TBL] [Abstract][Full Text] [Related]
46. Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.
Schlappe BA; Mueller JJ; Zivanovic O; Gardner GJ; Long Roche K; Sonoda Y; Chi DS; O'Cearbhaill RE
Gynecol Oncol; 2016 Jul; 142(1):13-18. PubMed ID: 27189456
[TBL] [Abstract][Full Text] [Related]
47. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer.
Zanon C; Clara R; Chiappino I; Bortolini M; Cornaglia S; Simone P; Bruno F; De Riu L; Airoldi M; Pedani F
World J Surg; 2004 Oct; 28(10):1040-5. PubMed ID: 15573262
[TBL] [Abstract][Full Text] [Related]
48. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
[TBL] [Abstract][Full Text] [Related]
49. Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
Bijelic L; Yan TD; Sugarbaker PH
Ann Surg Oncol; 2007 Aug; 14(8):2281-8. PubMed ID: 17503156
[TBL] [Abstract][Full Text] [Related]
50. Long-term survival after paclitaxel plus platinum-based combination chemotherapy for extraovarian peritoneal serous papillary carcinoma: is it different from that for ovarian serous papillary cancer?
Ayhan A; Taskiran C; Yigit-Celik N; Bozdag G; Gultekin M; Usubutun A; Guler N; Yuce K
Int J Gynecol Cancer; 2006; 16(2):484-9. PubMed ID: 16681715
[TBL] [Abstract][Full Text] [Related]
51. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
[TBL] [Abstract][Full Text] [Related]
52. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer.
Zang RY; Zhang ZY; Li ZT; Cai SM; Tang MQ; Chen J; Liu Q
Eur J Surg Oncol; 2000 Dec; 26(8):798-804. PubMed ID: 11087649
[TBL] [Abstract][Full Text] [Related]
53. Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy (HIPEC) by Minimally Invasive Approach, an Initial Experience.
Arjona-Sanchez A; Rufian-Peña S; Sanchez-Hidalgo JM; Casado-Adam A; Cosano-Alvarez A; Briceño-Delgado J
World J Surg; 2018 Oct; 42(10):3120-3124. PubMed ID: 29691625
[TBL] [Abstract][Full Text] [Related]
54. Prior Surgical Score: An Analysis of the Prognostic Significance of an Initial Nondefinitive Surgical Intervention in Patients With Peritoneal Carcinomatosis of a Colorectal Origin Undergoing Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy.
Paul BK; Ihemelandu C; Sugarbaker PH
Dis Colon Rectum; 2018 Mar; 61(3):347-354. PubMed ID: 29420428
[TBL] [Abstract][Full Text] [Related]
55. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.
Eisenkop SM; Friedman RL; Wang HJ
Gynecol Oncol; 1998 May; 69(2):103-8. PubMed ID: 9600815
[TBL] [Abstract][Full Text] [Related]
56. Hyperthermic intraperitoneal chemotherapy for the treatment of recurrent ovarian cancer in elderly women.
Delotte J; Arias T; Guerin O; Boulahssass R; Bereder I; Bongain A; Benchimol D; Bereder JM
Acta Obstet Gynecol Scand; 2015 Apr; 94(4):435-9. PubMed ID: 25675854
[TBL] [Abstract][Full Text] [Related]
57. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.
Matsumoto A; Higuchi T; Yura S; Mandai M; Kariya M; Takakura K; Fujii S
J Obstet Gynaecol Res; 2006 Dec; 32(6):580-7. PubMed ID: 17100820
[TBL] [Abstract][Full Text] [Related]
58. Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center.
Lee YJ; Chung YS; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
J Gynecol Oncol; 2018 Jul; 29(4):e63. PubMed ID: 29770632
[TBL] [Abstract][Full Text] [Related]
59. Primary psammocarcinoma of the ovary or peritoneum.
Poujade O; Uzan C; Gouy S; Pautier P; Duvillard P; Morice P
Int J Gynecol Cancer; 2009 Jul; 19(5):844-6. PubMed ID: 19574771
[TBL] [Abstract][Full Text] [Related]
60. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).
Cheng X; Jiang R; Li ZT; Tang J; Cai SM; Zhang ZY; Tian WJ; Zang RY
Eur J Surg Oncol; 2009 Oct; 35(10):1105-8. PubMed ID: 19443175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
